WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H328412
CAS#: 69956-77-0
Description: Pelubiprofen (also known as CS-670, DW-330, and RS-2131) is a prodrug of 2-arylpropionic acid with relatively selective effects on cyclooxygenase-2 activity. Pelubiprofen is a non-steroidal anti-inflammatory drugs that is related both structurally and pharmacologically to ibuprofen.
Hodoodo Cat#: H328412
Name: Pelubiprofen
CAS#: 69956-77-0
Chemical Formula: C16H18O3
Exact Mass: 258.13
Molecular Weight: 258.317
Elemental Analysis: C, 74.40; H, 7.02; O, 18.58
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Pelubiprofen; CS-670; DW-330; RS-2131; CS 670; DW 330; RS 2131; CS670; DW330; RS2131; Pelubi
IUPAC/Chemical Name: (E)-2-(4-((2-oxocyclohexylidene)methyl)phenyl)propanoic acid
InChi Key: AUZUGWXLBGZUPP-GXDHUFHOSA-N
InChi Code: InChI=1S/C16H18O3/c1-11(16(18)19)13-8-6-12(7-9-13)10-14-4-2-3-5-15(14)17/h6-11H,2-5H2,1H3,(H,18,19)/b14-10+
SMILES Code: CC(C1=CC=C(/C=C2C(CCCC/2)=O)C=C1)C(O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 258.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Ryu JH, Park JS, Jo MH, Kim JI, Shim WS, Kim BH, Yim SV, Hong J, Lee KT.
Development and validation of an LC-MS/MS method for the determination of
pelubiprofen and its active metabolite, trans-alcohol, in human plasma and its
application to pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life
Sci. 2015 Mar 1;983-984:62-7. doi: 10.1016/j.jchromb.2014.12.037. Epub 2015 Jan
15. PubMed PMID: 25618252.
2: Choi IA, Baek HJ, Cho CS, Lee YA, Chung WT, Park YE, Lee YJ, Park YB, Lee J,
Lee SS, Yoo WH, Song JS, Kang SW, Kim HA, Song YW. Comparison of the efficacy and
safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid
arthritis: a 6-week, multicenter, randomized, double-blind, phase III,
non-inferiority clinical trial. BMC Musculoskelet Disord. 2014 Nov 18;15:375.
doi: 10.1186/1471-2474-15-375. PubMed PMID: 25403311; PubMed Central PMCID:
PMC4247700.
3: Song SH, Chae BR, Sohn SI, Yeom DW, Son HY, Kim JH, Kim SR, Lee SG, Choi YW.
Formulation of controlled-release pelubiprofen tablet using Kollidon(®) SR. Int J
Pharm. 2016 Sep 25;511(2):864-75. doi: 10.1016/j.ijpharm.2016.07.074. Epub 2016
Aug 1. PubMed PMID: 27492018.
4: Shin JS, Baek SR, Sohn SI, Cho YW, Lee KT. Anti-inflammatory effect of
pelubiprofen, 2-[4-(oxocyclohexylidenemethyl)-phenyl]propionic acid, mediated by
dual suppression of COX activity and LPS-induced inflammatory gene expression via
NF-κB inactivation. J Cell Biochem. 2011 Dec;112(12):3594-603. doi:
10.1002/jcb.23290. PubMed PMID: 21809372.
5: Itoh K, Yamamoto K, Adachi M, Kosaka T, Tanaka Y. Leukotriene B4
12-hydroxydehydrogenase/15-ketoprostaglandin Delta 13-reductase (LTB4 12-HD/PGR)
responsible for the reduction of a double-bond of the alpha,beta-unsaturated
ketone of an aryl propionic acid non-steroidal anti-inflammatory agent CS-670.
Xenobiotica. 2008 Mar;38(3):249-63. doi: 10.1080/00498250701767667 . PubMed PMID:
18274955.
6: Asami M, Takasaki W, Iwabuchi H, Haruyama H, Wachi K, Terada A, Tanaka Y.
Stereospecific taurine conjugation of the trans-OH metabolite (active metabolite)
of CS-670, a new 2-arylpropionic acid nonsteroidal anti-inflammatory drug, in
dogs. Biol Pharm Bull. 1995 Nov;18(11):1584-9. PubMed PMID: 8593485.
7: Terada A, Naruto S, Wachi K, Tanaka S, Iizuka Y, Misaka E. Synthesis and
antiinflammatory activity of [(cycloalkylmethyl)phenyl]acetic acids and related
compounds. J Med Chem. 1984 Feb;27(2):212-6. PubMed PMID: 6607354.
8: Asami M, Shigeta A, Tanaka Y. Disposition of CS-670, a novel nonsteroidal
anit-inflammatory drug, and its metabolites in healthy human volunteers.
Chirality. 1996;8(2):207-13. PubMed PMID: 8857182.
9: Asami M, Yamamura M, Takasaki W, Tanaka Y. Quantitative determination of diol
metabolites of CS-670, a new antiinflammatory agent, by capillary column gas
chromatography-mass spectrometry. J Chromatogr B Biomed Appl. 1995 Mar
10;665(1):107-16. PubMed PMID: 7795780.
10: Takasaki W, Asami M, Muramatsu S, Hayashi R, Tanaka Y, Kawabata K, Hoshiyama
K. Stereoselective determination of the active metabolites of a new
anti-inflammatory agent (CS-670) in human and rat plasma using antibody-mediated
extraction and high-performance liquid chromatography. J Chromatogr. 1993 Mar
5;613(1):67-77. PubMed PMID: 8458904.
11: Kobayashi K, Abe C, Iizuka Y, Shiokawa Y. Immunomodulation by RS-2131, a new
non-steroidal antiinflammatory drug. Immunopharmacology. 1986 Dec;12(3):213-20.
PubMed PMID: 3546192.
